Biopharma | Government | Foundations | Research Institutes
BARDA - Rapidly advancing a Zika mRNA vaccine
In September 2016, Moderna received a funding award of up to $125 million from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to accelerate development of a novel Zika mRNA vaccine. Leveraging our research engine and early development engine, we were able to move our Zika mRNA vaccine from concept to IND in 10 months and concept to clinical study in 12 months.
Under the terms of the agreement with BARDA, an initial $8 million award is supporting a Phase 1 clinical study, toxicology studies, vaccine formulation and manufacturing. The agreement includes options for additional funding up to $117 million to support Phase 2 and Phase 3 clinical studies, as well as large-scale manufacturing.
DARPA – Advancing mRNA therapies and vaccines for biodefense
The Defense Advanced Research Projects Agency (DARPA) awarded Moderna up to $25 million to research and develop mRNA-based therapies and vaccines to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.
The grant is part of a DARPA program called ADEPT: PROTECT (Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats). The goal is to develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons, even in cases when the pathogen or infectious agent is unknown.
DARPA also provided a grant to Moderna to support preclinical work for Moderna’s Zika mRNA vaccine.